Corvus Pharmaceuticals/$CRVS
1D1W1MYTD1Y5YMAX
Capital at risk
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
- Ticker
- $CRVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 37
- Headquarters
- South San Francisco, United States
- Website
- www.corvuspharma.com
CRVS Metrics
BasicAdvanced
$1.1B
-
-$0.62
0.87
-
Price and volume
Market cap
$1.1B
Beta
0.87
52-week high
$26.95
52-week low
$5.74
Average daily volume
988K
Financial strength
Current ratio
16.162
Quick ratio
15.877
Long term debt to equity
0.001
Total debt to equity
0.003
Profitability
EBITDA (TTM)
-56.846
Management effectiveness
Return on assets (TTM)
-21.66%
Return on equity (TTM)
-35.43%
Valuation
Price to book
4.69
Price to tangible book (TTM)
4.69
Price to free cash flow (TTM)
-24.182
Free cash flow yield (TTM)
-4.14%
Free cash flow per share (TTM)
-0.519
Growth
Earnings per share change (TTM)
-38.47%
3-year earnings per share growth (CAGR)
-9.28%
10-year earnings per share growth (CAGR)
-17.73%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
Analyst projections of the future price of Corvus Pharmaceuticals stock.
Bulls say / Bears say
Peer-reviewed Phase 1/1b data showed durable activity in difficult-to-treat T-cell lymphoma: nine of 24 patients responded at the 200 mg twice-daily dose, including six complete responses, with median overall survival of 28.1 months. The treatment was well tolerated, with no dose-limiting toxicities or significant myelosuppression reported. (BioSpace, GlobeNewswire)
Soquelitinib also produced encouraging early results in atopic dermatitis. In the highest-dose, longest-treatment cohort, 75% of treated patients achieved EASI 75 versus 20% on placebo, while reported adverse events were mostly mild and occurred at the same rate as with placebo. (GlobeNewswire, The Motley Fool)
Corvus ended June with $215.2 million in cash, cash equivalents and marketable securities, which management expects to fund operations into the second quarter of 2028. That gives it time to run the pivotal lymphoma trial and several follow-on immune-disease studies before needing fresh funding under current plans. (GlobeNewswire, Last10K)
The key lymphoma evidence still needs to translate from an early-stage, non-randomised study into a randomised Phase 3 win against physician’s-choice treatment. An independent committee is expected to assess the Phase 3 trial for futility in the first quarter of 2027, and no results will be released at that checkpoint. (The Motley Fool, BioSpace)
Corvus has no approved product or product revenue and remains loss-making: second-quarter net loss widened to $18 million from $8 million, while research and development spending rose to $16 million from $7.9 million. The company says additional capital will be needed to fund all programmes through commercialisation, creating future financing and dilution risk. (Last10K, GlobeNewswire)
The atopic-dermatitis opportunity is based on small Phase 1 cohorts, with the strongest result coming from only 24 patients in the highest-dose cohort. The larger Phase 2 trial is not expected to complete enrolment until early 2027, with top-line data due in the third quarter of 2027, leaving a long period for the early signal to be disproved or delayed. (The Motley Fool, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRVS News
AllArticlesVideos
Funds containing CRVS
AllUSDGBPEUR
Fund name | Fund size | $CRVS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.